A Comprehensive Description of Hypoxia-inducible Factor 2α Inhibitors as Anticancer Agents: A Mini-review

Hongyuan Lu1, Yan Zhu1, Wenwu Liu2

  • 1Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, People's Republic of China.

Insights

Targeting hypoxia-inducible factor-2 alpha (HIF-2α) is crucial for cancer therapy. This review details HIF-2α inhibitors, aiding the development of novel anti-cancer drugs.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The tumor microenvironment, characterized by hypoxia, promotes cancer progression and drug resistance.
  • Hypoxia-inducible factors (HIFs), particularly HIF-2α, are key regulators in tumor hypoxia.
  • HIF-2α is implicated in various cancers, including renal cell carcinoma, breast, lung, and gastric cancers.

Approach:

  • This review categorizes and analyzes current research on HIF-2α inhibitors.
  • It focuses on the structure, structure-activity relationships (SAR), and pharmacology of these inhibitors.
  • Both specific (synthetic compounds, traditional Chinese medicine extracts) and non-specific inhibitors are discussed.

Key Points:

  • HIF-2α plays a significant role in multiple tumor types.
  • Targeting HIF-2α is a promising therapeutic strategy.
  • Understanding SAR is vital for designing effective HIF-2α inhibitors.

Conclusions:

  • HIF-2α inhibitors represent a critical area of cancer drug development.
  • This review provides a comprehensive overview to guide the rational design of new anti-cancer agents.
  • Further research into HIF-2α inhibitors can lead to improved cancer treatments.

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
14.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K